Treatment with growth hormone in the prader-willi syndrome.

Eugènia Moix Gil, Olga Giménez-Palop, Assumpta Caixàs

Journal: Endocrinologia, diabetes y nutricion 2019;65(4):229-236

PMID: 29510967

Full Text on Elsevier Science View on PubMed

Abstract

INTRODUCTION

The Prader-Willi syndrome (PWS) is a rare genetic disorder caused by absence of expression of the paternal alleles in región 15q11.2-q13. Obesity and hormonal deficiencies, especially of growth hormone (GH), are the most important signs from the therapeutic viewpoint. Recombinant GH (rGH) is effective in children and represents the mainstay in treatment; by contrast, little evidence in available in adult patients.

OBJECTIVE

To review the reported evidence on the beneficial and adverse effects of treatment with rGH in children and adults.

DESIGN

A review was made of 62 original articles published between 2000 and 2017 using the PubMed database.

RESULTS

In pediatric and adult PWS, rGH improves body morphology and composition, physical performance, cognition, psychomotor development, respiratory function, and quality of life with few adverse effects.

CONCLUSIONS

Treatment with rGH is effective and safe and improves quality of life in both children and adults with PWS.

Address: Facultad de Medicina, Unidad Docente Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, España.; Servicio de Endocrinología y Nutrición, Hospital Universitari Parc Tauli, , Sabadell, España.; Servicio de Endocrinología y Nutrición, Hospital Universitari Parc Tauli, , Sabadell, España. Electronic address: [email protected].

DOI: 10.1016/j.endinu.2018.01.006

Link outs

Free resources

Medical:

https://medlineplus.gov/praderwillisyndrome.html

Other Literature Sources:

https://scite.ai/reports/29510967

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Child, Human Growth Hormone, Humans, Prader-Willi Syndrome